OncoMatch/Clinical Trials/NCT06228482
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
Is NCT06228482 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. for metastatic nonsmall cell lung cancer.
Treatment: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. — This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ITGB6 overexpression (SUVmax >2-fold above normal bone, brain, lung or liver on [68Ga]Ga DOTA-5G PET/CT) (SUVmax >2-fold above normal bone, brain, lung or liver)
The presence of at least one measurable disease by [68Ga]Ga DOTA-5G PET/CT (SUVmax>2-fold above normal bone, brain, lung or liver and identified on standard of care diagnostic imaging)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: FDA approved systemic regimen — metastatic
documented tumor progression for metastatic disease during or following at least one prior FDA approved systemic regimen
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1000 cells/mm3; platelet count ≥ 100,000/mm3; hemoglobin ≥ 8 g/dl
Kidney function
creatinine ≤ 2 times uln
Liver function
ast, alt, alkaline phosphatase ≤ 5 times upper limit of normal (uln); total bilirubin ≤ 2 times uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06228482 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received FDA approved systemic regimen.
Does this trial require ITGB6?
Yes, ITGB6 overexpression (SUVmax >2-fold above normal bone, brain, lung or liver on [68Ga]Ga DOTA-5G PET/CT) is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages